The new AACR Cancer Disparities Progress Report is available online. The report provides a comprehensive overview of the latest research on cancer disparities and calls for policies to reduce disparities and achieve cancer health equity.
Read the ReportCancer is not a single disease, but rather a collection of diseases all characterized by the uncontrolled proliferation of cells.
Learn MoreTargeting “Undruggable” Proteins That Drive Cancer: AACR grantee Raymond E. Moellering, PhD, uses chemistry to build “molecules that can go after undruggable protein targets” to treat cancers.
Read AACR StoriesNearly 153,000 people in the U.S. are expected to be diagnosed with colorectal cancer this year. Read about the prevention, screening, and treatment options for this type of cancer.
Learn MoreInvesting in Innovation: The AACR grants program sparks innovation in basic, translational, and clinical research by providing critical support to promising investigators at all career levels.
Read MoreThe Week in Cancer News: A roundup of significant cancer research news from the past week, selected by the staff of Cancer Today magazine.
Learn MoreWhether honoring a special person or a special day, a donation to the American Association for Cancer Research has a lasting impact.
Donate NowSession recordings are available for viewing to registered attendees through July 10. Registration remains open for the on-demand virtual meeting.
The AACR Cancer Disparities Progress Report 2024 outlines the complex interplay of factors that drive and perpetuate cancer health disparities and calls for a collaborative approach to achieve health equity.
Learn MoreThe AACR and its more than 58,000 members worldwide are advancing a scientifically bold agenda against the collection of diseases we call cancer.
Learn MoreDr. Winn, chair of the AACR Cancer Disparities Progress Report 2024 steering committee, discusses the many factors that drive and perpetuate cancer health disparities.
Learn Morepercent decrease of the overall age-adjusted cancer death rate in the U.S. from 1991 to 2020
Learn Moretherapeutics were approved for new or expanded uses by the FDA from Aug. 1, 2022, to July 31, 2023
Learn Moremillion cancer survivors in the U.S. are living with, through, and beyond their disease thanks to research
Learn More